ReviewEngineered affinity proteins—Generation and applications
Section snippets
Generation of novel affinity proteins by selection from protein libraries
Evolution has generated the great diversity of proteins with all different features required for the processes of life primarily by using the 20 amino acids available in nature. Despite all our efforts to fully understand the nature of proteins, we are still far from being able to create completely new proteins with desired structure and function merely by rational design. By utilizing state-of-the-art in vitro evolution technology it is possible to generate protein variants with new features.
Engineered antibody fragments
Through the evolution the immune system has developed the capability of producing antibodies specific for almost any molecule. Because of their exceptional properties of natural molecular recognition, antibodies have been intensely studied and used in many areas of biological research, biotechnology and for medical diagnostics and therapy. Monoclonal antibodies are excellent affinity proteins, but the intact antibody format suffers from some disadvantages for certain applications. Antibodies
Alternative protein scaffolds
The success of antibody engineering and the increasing experience in the field of combinatorial libraries and protein engineering have inspired researchers to develop new non-immunoglobulin affinity protein lacking the inherent limitations of antibodies. Consequently, today antibodies and antibody derivatives are facing increasing competition from a large number so-called engineered protein scaffolds (Hosse et al., 2006). The term “scaffold” reflects the use of a protein framework that can
Biotechnology research reagents and separation ligands
Engineered alternative scaffolds are in many aspects well suited for biotechnology applications (Fig. 3). Generally, high biophysical stability, long shelf-life and convenient expression at high yields in a prokaryotic host, gives cost-efficient production of engineered affinity proteins, when compared to conventional antibodies. One area of biotechnology applications that have attracted increased attention is the use of engineered affinity proteins as capture agents in affinity matrices. In
Concluding remarks
Engineered affinity proteins are foreseen to have an expanding role in biotechnology, biological science and medical applications in the future. Investigations of independent novel engineered proteins imply that it is possible to generate artificial binding proteins comparable to conventional antibodies in terms of specificity and affinity. However, to truly be able to compete with the well-established antibody technology, engineered protein scaffolds have to display properties superior to that
References (168)
- et al.
Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins
J. Biol. Chem.
(2005) - et al.
Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies
J. Immunol. Methods
(2003) - et al.
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins
J. Mol. Biol.
(2003) - et al.
Yeast surface display for directed evolution of protein expression, affinity, and stability
Methods Enzymol.
(2000) Antibodies in diagnostics—from immunoassays to protein chips
Immunol. Today
(2000)- et al.
Antibodies from phage antibody libraries
J. Immunol. Methods
(2004) PEGylated antibodies and antibody fragments for improved therapy: a review
Adv. Drug Deliv. Rev.
(2002)Protein engineering with bacterial display
Curr. Opin. Struct. Biol.
(2007)- et al.
Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display
J. Biol. Chem.
(1994) - et al.
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor 1-binding affibody molecule
J. Mol. Biol.
(2008)
Yeast surface display for protein engineering and characterization
Curr. Opin. Struct. Biol.
Biopharmaceutical drug discovery using novel protein scaffolds
Curr. Opin. Biotechnol.
A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products
J. Biotechnol.
Selection and characterization of affibody ligands binding to Alzheimer amyloid beta peptides
J. Biotechnol.
An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein
Immunotechnology
Artificial, non-antibody binding proteins for pharmaceutical and industrial applications
Trends Biotechnol.
Domain antibodies: proteins for therapy
Trends Biotechnol.
Natural and designer binding sites made by phage display technology
Immunol. Today
Use of bacteriophage T7 displayed peptides for determination of monoclonal antibody specificity and biosensor analysis of the binding reaction
Anal. Biochem.
All individual domains of staphylococcal protein A show Fab binding
FEMS Immunol. Med. Microbiol.
Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold
J. Mol. Biol.
Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain
Chem. Biol.
Dual labeling of a binding protein allows for specific fluorescence detection of native protein
Anal. Biochem.
Direct selection of antibodies from complex libraries with the protein fragment complementation assay
J. Mol. Biol.
Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein
Structure
The fibronectin type III domain as a scaffold for novel binding proteins
J. Mol. Biol.
Evaluation of antibodies fused to minor coat protein III and major coat protein VIII of bacteriophage M13
Gene
Structural basis for molecular recognition in an affibody:affibody complex
J. Mol. Biol.
In-vitro protein evolution by ribosome display and mRNA display
J. Immunol. Methods
Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display
FEMS Microbiol. Lett.
Site-specifically conjugated anti-HER2 affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples
J. Immunol. Methods
In vitro virus: bonding of mRNA bearing puromycin at the 3′-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro
FEBS Lett.
Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries
Protein Eng. Des. Sel.
EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis
J. Pharmacol. Exp. Ther.
Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin
Acta Crystallogr. D: Biol. Crystallogr.
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site
Proc. Natl. Acad. Sci. U.S.A.
Phage Display: A Laboratory Manual
Hormone phage: an enrichment method for variant proteins with altered binding proterties
Proteins: Struct. Funct. Genet.
A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an indium-111- or gallium-68-labelled affibody molecule. Abstracts of Annual Congress of the European Association of Nuclear Medicine, Athens, Greece (2006)
Eur. J. Nucl. Med. Mol. Imaging
Selection of single domain binding proteins by covalent DNA display
Protein Eng. Des. Sel.
Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold
Proc. Natl. Acad. Sci. U.S.A.
High-affinity binders selected from designed ankyrin repeat protein libraries
Nat. Biotechnol.
Engineering novel binding proteins from nonimmunoglobulin domains
Nat. Biotechnol.
Single-chain antigen-binding proteins
Science
Yeast surface display for screening combinatorial polypeptide libraries
Nat. Biotechnol.
Peptide aptamers: recent developments for cancer therapy
Expert Opin. Biol. Ther.
Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists
Nat. Med.
Potent antibody therapeutics by design
Nat. Rev. Immunol.
Isolating and engineering human antibodies using yeast surface display
Nat. Protoc.
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody
Proc. Natl. Acad. Sci. U.S.A.
Cited by (87)
Mechanisms of amyloid proteins aggregation and their inhibition by antibodies, small molecule inhibitors, nano-particles and nano-bodies
2021, International Journal of Biological MacromoleculesOptical microchips based on high-affinity recombinant protein binders—Human serum albumin detection in urine
2018, Sensors and Actuators, B: ChemicalA dimeric form of a small-sized protein binder exhibits enhanced anti-tumor activity through prolonged blood circulation
2018, Journal of Controlled ReleaseCitation Excerpt :Over the past decade, non-antibody protein scaffolds with a small size (<~30 kDa) have drawn considerable attention as alternatives to immunoglobulin antibodies, and diverse scaffolds have been developed, showing the possibility of their wide applications in many areas [1–8].
The development and optimisation of nanobody based electrochemical immunosensors for IgG
2016, Sensors and Actuators, B: ChemicalA label-free electrochemical affisensor for cancer marker detection: The case of HER2
2015, Bioelectrochemistry